The long-term use of calcium channel blockers and the risk of breast cancer.

Soldera, Sara V.; Bouganim, Nathaniel; Asselah, Jamil; Yin, Hui; Maroun, Ralph; Azoulay, Laurent

doi:10.1200/jco.2015.33.15_suppl.1588

Cited by 3 publications

(9 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There was an inconsistent duration-response relationship for the CCB versus other AHT metaregression. The log relative risk against minimum follow-up time for log odds/risk ratio had a regression coefficient 0.047 (95% CI 0.007 -0.086, p = 0.02, 5 studies/sub-studies (35,40,45,46,54): 0.06 for female only studies), whilst for log hazard ratio, only one study was included (51), and no duration-response effect was seen (regression coefficient = 0.006, 95%…”

Section: Synthesis Of Resultsmentioning

confidence: 99%

“…Database searching returned 2,099 unduplicated records of which 58 articles underwent full-text review. Twenty articles fulfilled the eligibility criteria (33)(34)(35)(36)(37)(38)(39)(40)(41)(42)(43)(44)(45)(46)(47)(48)(49)(50)(51)(52).…”

Section: Study Selectionmentioning

confidence: 99%

“…A further 956 unduplicated articles were identified via reference and citation checking; nine of these fulfilled the eligibility criteria (54)(55)(56)(57)(58)(59)(60)(61)(62). For the three eligible records only available as conference abstracts (42,49,51), the authors sent a Wright, C. and Moorin, R. and Chowdhury, E. and Stricker, B. and Reid, C. and Saunders, C. and Hughes, J. 2017.…”

Section: Study Selectionmentioning

confidence: 99%

“…For example, one study included women aged 55 to 74 years (46), whereas an earlier study had a mean age of 79 years (60). The length of follow-up varied, with some studies conducting a discrete analysis for CCB use exceeding 10 years (37,45,46,49,51). The majority of studies (27/29) used data from Europe or North America, with the exception of two recent studies from Taiwan (35,44).…”

Section: Study Characteristicsmentioning

confidence: 99%

“…While some studies specifically focused on the risk of breast cancer associated with CCB use (34,38,42,47,49,51), the remainder either explored the risk of breast cancer or cancer overall associated with AHTs, or the risk of cancer overall associated with CCBs. Older studies tended to include more patients taking immediate-release/short-acting CCBs, as prescribing trends changed to include more sustained-release/longer-acting CCBs in newer studies.…”

mentioning

confidence: 99%

See 4 more Smart Citations

Calcium channel blockers and breast cancer incidence: An updated systematic review and meta-analysis of the evidence

Wright

Moorin

Chowdhury

et al. 2017

Cancer Epidemiology

View full text Add to dashboard Cite

Controversy exists regarding the potential association between taking calcium channel blockers (CCBs) and the development of breast cancer. As a positive association would have important public health implications due to the widespread use of CCBs, this study aimed to incorporate new evidence to determine whether an association is likely to exist. We searched MEDLINE, EMBASE and the Cochrane Library to 28 June 2016 for relevant literature. References and citing articles were checked and authors contacted as necessary. Two authors independently selected articles and extracted data. Twenty-nine studies were reviewed; 26 were non-randomised studies (NRS). Meta-analysis of study data where adjustment for 'confounding by indication' was judged to be present suggests that an association, if any, is likely to be modest in magnitude (pooled odds/risk ratio 1.09 (95% confidence interval (CI) 1.03-1.15, I=0%, 8 sub-studies; pooled hazard ratio 0.99 (95% CI 0.94-1.03, I=35%, 9 sub-studies)). There are credible study data showing an increased relative risk with long-term use of CCBs, but the results of our meta-analysis and of meta-regression of log relative risk against minimum follow-up time are mixed. The current summative evidence does not support a clear association between taking CCBs and developing breast cancer. However, uncertainty remains, especially for long-term use and any association might not be uniform between different populations and/or breast cancer sub-types. We thus recommend further NRS in settings where CCB use is highly prevalent and population-based cancer, prescription and health-registries exist, to resolve this continuing uncertainty. PROSPERO, CRD42015026712.

show abstract

Section: Synthesis Of Resultsmentioning

confidence: 99%

Section: Study Selectionmentioning

confidence: 99%

Section: Study Selectionmentioning

confidence: 99%

Section: Study Characteristicsmentioning

confidence: 99%

mentioning

confidence: 99%

See 3 more Smart Citations

Calcium channel blockers and breast cancer incidence: An updated systematic review and meta-analysis of the evidence

Wright

Moorin

Chowdhury

et al. 2017

Cancer Epidemiology

View full text Add to dashboard Cite

show abstract

Calcium signaling affects migration and proliferation differently in individual cancer cells due to nifedipine treatment

Chovancova

Lišková

Miklikova

et al. 2020

Biochemical Pharmacology

View full text Add to dashboard Cite

Antihypertensive drug use and breast cancer risk: a meta-analysis of observational studies

Qin

Zhu

et al. 2017

Oncotarget

View full text Add to dashboard Cite

We conducted a meta-analysis of observational studies to examine the hypothesized association between breast cancer and antihypertensive drug (AHT) use. Fixed- or random- effect models were used to calculate pooled risk ratios (RRs) and 95% confidence intervals (CIs) for all AHTs and individual classes (i.e., angiotensin-converting enzyme inhibitors, [ACEi]; angiotensin-receptor blockers, [ARBs]; calcium channel blockers, [CCBs]; beta-blockers, [BBs], and diuretics). Twenty-one studies with 3,116,266 participants were included. Overall, AHT use was not significantly associated with breast cancer risk (RR = 1.02, 95% CI: 0.98-1.06), and no consistent association was found for specific AHT classes with pooled RRs of 1.02 (95% CI: 0.96-1.09) for BBs, 1.07 (95% CI: 0.99-1.16) for CCBs, 0.99 (95% CI: 0.93-1.05) for ACEi/ARBs, and 1.05 (95% CI: 0.99-1.12) for diuretics. When stratified by duration of use, there was a significantly reduced breast cancer risk for ACEi/ARB use ≥10 years (RR = 0.80, 95% CI: 0.67-0.95). Although there was no significant association between AHT use and breast cancer risk, there was a possible beneficial effect was found for long-term ACEi/ARB. Large, randomized controlled trials with long-term follow-up are needed to further test the effect of these medications on breast cancer risk.

show abstract

The long-term use of calcium channel blockers and the risk of breast cancer.

Cited by 3 publications

References 24 publications

Calcium channel blockers and breast cancer incidence: An updated systematic review and meta-analysis of the evidence

Calcium channel blockers and breast cancer incidence: An updated systematic review and meta-analysis of the evidence

Calcium signaling affects migration and proliferation differently in individual cancer cells due to nifedipine treatment

Antihypertensive drug use and breast cancer risk: a meta-analysis of observational studies

Contact Info

Product

Resources

About